Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Josefa dela Cruz-Chuh"'
Autor:
Josefa Dela Cruz Chuh, MaryAnn Go, Yvonne Chen, Jun Guo, Hanine Rafidi, Danielle Mandikian, Yonglian Sun, Zhonghua Lin, Kellen Schneider, Pamela Zhang, Rajesh Vij, Danielle Sharpnack, Pamela Chan, Cecile de la Cruz, Jack Sadowsky, Dhaya Seshasayee, James T. Koerber, Thomas H. Pillow, Gail D. Phillips, Rebecca K Rowntree, C. Andrew Boswell, Katherine R. Kozak, Andrew G. Polson, Paul Polakis, Shang-Fan Yu, Peter S. Dragovich, Nicholas J. Agard
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of thes
Externí odkaz:
https://doaj.org/article/25ec46df098b446591f757fd46270d3e
Autor:
Aimee Fourie-O’Donohue, Phillip Y. Chu, Josefa dela Cruz Chuh, Robert Tchelepi, Siao Ping Tsai, John C. Tran, William S. Sawyer, Dian Su, Carl Ng, Keyang Xu, Shang-Fan Yu, Thomas H. Pillow, Jack Sadowsky, Peter S. Dragovich, Yichin Liu, Katherine R. Kozak
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
For antibody-drug conjugates to be efficacious and safe, they must be stable in circulation to carry the payload to the site of the targeted cell. Several components of a drug-conjugated antibody are known to influence stability: 1) the site of drug
Externí odkaz:
https://doaj.org/article/e46e20ec184a4063ba55b87d5b9f2d28
Autor:
Thomas H. Pillow, Andrew G. Polson, Peter S. Dragovich, Hans K. Erickson, Pragya Adhikari, John Wai, Zijin Xu, Jinhua Chen, Katherine R. Kozak, Josefa dela Cruz-Chuh, Keyang Xu, Carl Ng, Amrita V. Kamath, Douglas D. Leipold, Shang-Fan Yu, Mary Ann T. Go, Geoffrey del Rosario, Fiona Zhong, Melissa M. Schutten, Chris Frantz, Breanna S. Vollmar
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5429ac6c382f94a2b29d630d8d1ebd26
https://doi.org/10.1158/1535-7163.22522233
https://doi.org/10.1158/1535-7163.22522233
Autor:
C. Andrew Boswell, Leslie A. Khawli, Paul J. Fielder, Frank-Peter Theil, Jay Tibbitts, Mark Sliwkowski, Daniela Bumbaca, Peter Nauka, Nicholas Lewin-Koh, Katherine R. Kozak, Josefa dela Cruz Chuh, Sheila Bheddah, Nicholas Majidy, Marjie Van Hoy, Gary Cain, Kathryn Parsons-Reponte, Eric Cheng, Sarajane Ross, Suzanna Clark, Sheila Ulufatu, Jason Ho, Tapan K. Nayak, Simon P. Williams, Eduardo E. Mundo, Cinthia V. Pastuskovas
PDF file - 87K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00fc2d00b11995f6f3d87ea8b565c1d6
https://doi.org/10.1158/1535-7163.22498423.v1
https://doi.org/10.1158/1535-7163.22498423.v1
Autor:
Thomas H. Pillow, Andrew G. Polson, Peter S. Dragovich, Hans K. Erickson, Pragya Adhikari, John Wai, Zijin Xu, Jinhua Chen, Katherine R. Kozak, Josefa dela Cruz-Chuh, Keyang Xu, Carl Ng, Amrita V. Kamath, Douglas D. Leipold, Shang-Fan Yu, Mary Ann T. Go, Geoffrey del Rosario, Fiona Zhong, Melissa M. Schutten, Chris Frantz, Breanna S. Vollmar
Calicheamicin antibody–drug conjugates (ADCs) are effective therapeutics for leukemias with two recently approved in the United States: Mylotarg (gemtuzumab ozogamicin) targeting CD33 for acute myeloid leukemia and Besponsa (inotuzumab ozogamicin)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::953a865f6922c43da57998015e9032ac
https://doi.org/10.1158/1535-7163.c.6543312.v1
https://doi.org/10.1158/1535-7163.c.6543312.v1
Autor:
C. Andrew Boswell, Leslie A. Khawli, Paul J. Fielder, Frank-Peter Theil, Jay Tibbitts, Mark Sliwkowski, Daniela Bumbaca, Peter Nauka, Nicholas Lewin-Koh, Katherine R. Kozak, Josefa dela Cruz Chuh, Sheila Bheddah, Nicholas Majidy, Marjie Van Hoy, Gary Cain, Kathryn Parsons-Reponte, Eric Cheng, Sarajane Ross, Suzanna Clark, Sheila Ulufatu, Jason Ho, Tapan K. Nayak, Simon P. Williams, Eduardo E. Mundo, Cinthia V. Pastuskovas
PDF file - 93K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00ef0436e7f6dbaf1070a8a11a7cc5ef
https://doi.org/10.1158/1535-7163.22498426.v1
https://doi.org/10.1158/1535-7163.22498426.v1
Autor:
Andrew G. Polson, Mark X. Sliwkowski, Robert W. Akita, Byoung-Chul Lee, Benjamin Haley, Qui Phung, Tommy K. Cheung, Jack Sadowsky, Thomas H. Pillow, Yichin Liu, Katherine R. Kozak, Donglu Zhang, Yong Ma, Josefa dela Cruz Chuh, Niña G. Caculitan
Supplementary Figure 5: Control spectrum obtained via quantitative LC-MS for the anti-HER2-VC(S)-MMAE ADC after 3 hours with in buffer with no proteolytic solution.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbcee4c6000a7344ad67ea80f2ffb1d8
https://doi.org/10.1158/0008-5472.22416947.v1
https://doi.org/10.1158/0008-5472.22416947.v1
Autor:
Andrew G. Polson, Mark X. Sliwkowski, Robert W. Akita, Byoung-Chul Lee, Benjamin Haley, Qui Phung, Tommy K. Cheung, Jack Sadowsky, Thomas H. Pillow, Yichin Liu, Katherine R. Kozak, Donglu Zhang, Yong Ma, Josefa dela Cruz Chuh, Niña G. Caculitan
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a52077034dd3017dea4fca6c949c037c
https://doi.org/10.1158/0008-5472.22416935.v1
https://doi.org/10.1158/0008-5472.22416935.v1
Autor:
Andrew G. Polson, Mark X. Sliwkowski, Robert W. Akita, Byoung-Chul Lee, Benjamin Haley, Qui Phung, Tommy K. Cheung, Jack Sadowsky, Thomas H. Pillow, Yichin Liu, Katherine R. Kozak, Donglu Zhang, Yong Ma, Josefa dela Cruz Chuh, Niña G. Caculitan
Antibody–drug conjugates (ADC) are designed to selectively bind to tumor antigens via the antibody and release their cytotoxic payload upon internalization. Controllable payload release through judicious design of the linker has been an early techn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35b8ea5d91de0b8b1b320419f56d8e61
https://doi.org/10.1158/0008-5472.c.6509693.v1
https://doi.org/10.1158/0008-5472.c.6509693.v1
Autor:
Peter S. Dragovich, Mingtao He, Leanna Staben, Hongyan Zhang, Melinda M. Mulvihill, Catherine Wilson, Hao Zhou, Tracy Kleinheinz, Binqing Wei, Jianfeng Xin, Nicole Blaquiere, Fanwei Meng, John S. Wai, Susan Kaufman, Liang Liu, Rebecca K. Rowntree, Steven T. Staben, Jing Wang, Katherine R. Kozak, Josefa dela Cruz-Chuh, Zijin Xu, Steven J. Hartman, Robert A. Blake, Xiaoyu Zhu, Sunil Bhakta, Donglu Zhang, Hui Yao, Aimee O'Donohue, Jack Sadowsky, Qi Liu, Pragya Adhikari, Liling Liu, Ying Lu, Thomas H. Pillow, Jinhua Chen, Emel Adaligil, Karen E. Gascoigne
Publikováno v:
Journal of Medicinal Chemistry. 64:2534-2575
The biological and medicinal impacts of proteolysis-targeting chimeras (PROTACs) and related chimeric molecules that effect intracellular degradation of target proteins via ubiquitin ligase-mediated ubiquitination continue to grow. However, these chi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eaea12dee6f95904b15f4c9e925d0b1
https://doi.org/10.1021/acs.jmedchem.0c01845
https://doi.org/10.1021/acs.jmedchem.0c01845